# CONSULTANCY AGREEMENT

**Between:**

**Regla ApS** (CVR no. 45462013)
Dalgas Boulevard 48, 2000 Frederiksberg
("Regla")

**and**

**OptoCeutics A/S** (CVR no. 39769689)
Nørrebrogade 45C, 4. tv., 2200 København N
("OptoCeutics")

**Date:** [________] 2026

---

## Background

A. Regla develops a proprietary AI-powered electronic Quality Management System (E-QMS) for medical device manufacturers, incorporating automated documentation generation, clinical and regulatory data analysis, and regulatory strategy support (the "Platform").

B. OptoCeutics wishes to engage Regla to provide consulting services related to quality management, regulatory documentation, and regulatory strategy using the Platform.

---

## 1. Services

1.1. Regla will provide consulting services to OptoCeutics as an independent contractor. Regla performs the services independently and at its own discretion.

1.2. The specific activities, timelines, and priorities will be agreed between the Parties on an ongoing basis. Neither Party is obligated to commit a minimum number of hours or resources unless separately agreed in writing.

1.3. The services under this Agreement are provided without separate cash payment. Each Party bears its own costs unless otherwise agreed in writing.

## 2. Intellectual Property

2.1. Regla owns all intellectual property rights in the Platform, including any improvements, features, or functionality developed during or as a result of this engagement.

2.2. Regla grants OptoCeutics a non-exclusive, non-transferable license to use the Platform source code for OptoCeutics' own internal purposes and in OptoCeutics' own products and services. OptoCeutics shall not distribute, sublicense, or otherwise make the source code available to third parties, nor use the source code to develop, market, or offer to third parties any product or service that competes with the Platform. In the event of a change of control of OptoCeutics (including acquisition, merger, or sale of a majority of shares), the source code license shall be limited to OptoCeutics' business activities as conducted at the time of the change of control.

## 3. Confidentiality

3.1. Each Party shall keep confidential all non-public information received from the other Party in connection with this engagement ("Confidential Information"), including the Platform source code, algorithms, architecture, QMS documentation, and business information.

3.2. The confidentiality obligation does not apply to information that: (a) becomes publicly available through no fault of the receiving Party; (b) was already known to the receiving Party; (c) is independently developed without use of the Confidential Information; or (d) is required to be disclosed by law, provided the disclosing Party is notified in advance where possible.

3.3. The obligations in this Section 3 survive termination for three (3) years.

## 4. Liability

4.1. Neither Party shall be liable for indirect or consequential losses, including loss of profit, loss of business, or loss of data.

4.2. Each Party's aggregate liability shall not exceed EUR 50,000, except in cases of gross negligence, wilful misconduct, or breach of Section 3.

## 5. Term and Termination

5.1. This Agreement enters into force on the date of signing and continues for an indefinite period. Either Party may terminate for any reason by giving three (3) months' written notice.

5.2. Either Party may terminate with immediate effect if the other Party commits a material breach not remedied within thirty (30) days of written notice, or becomes insolvent.

5.3. Upon termination, Sections 2, 3, and 4 survive.

## 6. General

6.1. This Agreement is governed by Danish law. Disputes shall be settled by the ordinary Danish courts, with the Copenhagen City Court (Københavns Byret) as the court of first instance.

6.2. Amendments must be in writing and signed by both Parties. This Agreement constitutes the entire agreement between the Parties on the subject matter.

---

**For Regla ApS:**

Name: ________________________
Title: ________________________
Date: ________________________
Signature:

________________________

&nbsp;

**For OptoCeutics A/S:**

Name: ________________________
Title: ________________________
Date: ________________________
Signature:

________________________
